november AG
november AG english
Strategic partnership with Siemens Medical Solutions
Ad-hoc-announcement transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
Erlangen, 6 November 2003. Today, november AG and Siemens Medical Solutions
announce the conclusion of a strategic partnership to develop technologies for
blood diagnosis at the point of care: november’s LabChip products replace costly
laboratory infrastructure and revolutionize the blood-based detection of
viruses, cancer cells and genetic risk factors. On the basis of today’s
contract, both strategic partners, the Erlangen-based biotech company november
AG (ISIN DE0006762909) and Siemens Medical Solutions (Med), believe that market
launch of the extremely compact systems will be achieved as early as in the end
of 2004. The partners will jointly conduct further development and production of
november’s diagnostic LabChip products. Financial terms of the agreement were
not disclosed. Through this agreement, both partners will strengthen their
leading position in biotech diagnostics. The new contract expands the existing
successful R&D cooperation that dates back to the fall of 2001.
The world’s first fully integrated system for on-site testing of nucleic acids
at the point-of-care needs only one drop of blood or other biological liquids.
The user benefits from significant cost-reductions and a drastically reduced
time for data analysis.
The two components of the system are a cartridge and a main analyzer unit. The
cartridge contains the reagents as well as all functional domains necessary for
the isolation of DNA or RNA, amplification of nucleic acids to facilitate
detection and the subsequent electrochemical analysis of currently up to 99
genetic parameters per sample. This extremely compact and cost-efficient device
was developed on the basis of november’s patented marker free detection system
with carbon plastic electrodes and by applying advanced fluidic techniques for
the integration of all processing steps. Process control and electronic signal
evaluation is carried out by the analyzer, a joint development with Siemens.
According to november AG, the addressable market for the system today has a
volume in the 1 billion Euro range already.
Further information: Dr. Peer Nils Schroeder
november AG – Investor Relations/Public Relations
Tel. +49 (0)9131 750 88 868, schroeder@november.de
end of ad-hoc-announcement (c)DGAP 06.11.2003
——————————————————————————–
WKN: 676290; ISIN: DE0006762909; Index:
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin-
Bremen, Düsseldorf, Hannover, München und Stuttgart
060731 Nov 03
Aktuelle News
Aktuelle Berichte
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden